endoscopic ultrasonography (EUS) is a technology that perfectly combines endoscopy and ultrasound, known as the "third eye" of endoscopists, which combines the advantages of "endoscopy" and "ultrasound", allowing endoscopists to have the ability of "perspective" on the basis of "direct vision". Real-time scanning with endoscopic ultrasound can obtain the histological features of the digestive tract hierarchy and the ultrasound images of neighboring organs for examination.

Endoscopic ultrasound can be further divided into micro-probe endoscopic ultrasound (commonly known as small ultrasound) and line array and ring array endoscopic ultrasound (commonly known as large ultrasound) according to different probes. Among them, the small super has the characteristics of flexibility, ease of use, high resolution and lower cost, and has great application value in clinical practice.

Compared with the ordinary endoscope, the technical barriers of ultrasonic endoscope are higher, and the ultrasonic endoscope and ultrasonic microprobe products have been monopolized by the three major manufacturers of Olympus, Fuji and Pentax. Domestic small super has not reached a zero breakthrough until recent years, to achieve market-oriented application, but the speed of domestic substitution is very rapid, which has formed a strong impact on the control of foreign giants.

2023 small super bidding big data

Domestic brands take the lead

According to the statistics of China's micro-probe endoscopic ultrasound bidding in 2023, the domestic brand Anglo American has occupied more than half of the domestic micro-probe endoscopic ultrasound in 2023, occupying the first place with 51% of the market. Fujifilm is second with a 40% market share. The combined market share of the two sides exceeds 90%, forming an absolute leading advantage.

Domestic brands Open and Lepu (Huacke Chuangzhi) with 7% and 2%, respectively, ranked third and fourth.

2024年上半年小超招投标数据

The domestic share has increased significantly

Bidding data in the first half of 2024 show that the market share of domestic brands has further increased to 58%, continuing to occupy the first place in the market; China Open jumped to second place with 18% market share.

Fujifilm's share of the market has fallen significantly to 16%; Lepu (Huake Chuangzhi) also achieved an increase in share, ranking fourth with 8%.

Compared with the annual market share in 2023, domestic brands have grown rapidly in the first half of 2024, and have formed a encircling trend. The total market share of domestic brands increased significantly from 60.5% in 23 years to 84.3% in the first half of 24 years, occupying an absolute dominant position.

The rise of the three domestic giants

According to a business report published by Allied Market Research, the global EUS market size was $1.2 billion in 2021 and is expected to reach $2.2 billion by 2031, with a compound annual growth rate of 6.1% from 2022 to 2031.

Traditional global endoscopy giants mainly include Olympus, Fujifilm, Pentax Medical, Boston Scientific, Medtronic, Cook Medical and so on. Local endoscopic ultrasound enterprises mainly include Shenzhen British American Medical Technology, Shenzhen Open biomedical technology, Beijing Huakuangzhi Health technology and so on.

From the above market bidding data, the above three companies have grown into small super three giants in the domestic market and are rising rapidly. Under the leadership of the domestic small super three giants, the category of micro-probe ultrasound endoscopy in China continues to expand.

British American to break the domestic blank

In August 2021, the innovative medical device "ultrasonic diagnostic equipment for Endoscopy" independently developed by Anglo American successfully obtained the approval of the State Food and Drug Administration and obtained the registration certificate of third class medical devices. This is the first approved miniaturized high-frequency ultrasonic small probe product in China, and the third in the world after Olympus and Fujifilm.

In the middle of 2023, The world's first dual-frequency ultrasonic diagnostic equipment (Neptune series iMP-8806, iMP-8807), the first circular scan dual-frequency ultrasonic small probe (DP-21, DP-21G), the first portable integrated ultrasonic diagnostic equipment (iMP-8901, iMP-8903), the first dual-frequency small probe in respiratory department (DP-21M) were obtained Approved by the National Medical Products Administration (NMPA), the product layout and solutions in the field of digestion and respiration have been further enriched and improved, and the clinical level and confidence in the diagnosis of digestive tract, pancreatic duct and respiratory tract have been improved.

Establish medical treatment to assist lung diagnosis and treatment

In April 2023, the ultrasonic probe for bronchoendoscopy (UM-1720) developed by the medical subsidiary Love Sound Biology was officially approved by NMPA, becoming the first in China and the third in the world to be approved, and truly applied the ultrasonic probe for endoendoscopy to clinical enterprises.

Lepu achieves endoscopic ultrasound layout

Lepu Medical acquired Beijing Huake Chuangzhi Company in 2021. In June 2022, Huakochuangchi Vsonic 600 ultrasonic diagnostic equipment for gastrointestinal endoscopy (small gastrointestinal ultrasound) obtained NMPA registration certificate, and began to promote industrialization and achieve business income in 2023.

Endoscopic ultrasound has outstanding advantages in determining the nature of gastrointestinal lesions, judging the invasion depth and scope of gastrointestinal malignant tumors, and diagnosing diseases of the pancreatic system.

According to the World Health Organization, the number of new cases of gastric cancer and esophageal cancer in China in 2020 will be 479,000 and 324,000, accounting for 44.0% and 53.70% of new cases of gastric cancer and esophageal cancer in the world, respectively. According to the latest data in China in 2020, the incidence of gastric cancer and esophageal cancer ranked third and sixth respectively among various malignant tumors, which indicates that endoscopic ultrasound has a broad market space in China. So in the future, what changes will occur in the domestic endoscopy market, the home of instruments will continue to pay attention to.